Condition

Multiple Myeloma, Refractory clinical trials and research

• 21Clinical trials
• 10Countries

Newest Multiple Myeloma, Refractory clinical trials

All recruiting trials (21)

• In Vivo BCMA-CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma

  This study tests VV169, a one-time in vivo CAR-T treatment, in adults with multiple myeloma that has come back or not responded to standard therapy.

  Recruiting Phase 1 Vyriad, Inc. · Rochester, Minnesota · NCT07802717

• Inobrodib with Pomalidomide and Dexamethasone vs Standard Therapy for Relapsed or Refractory Myeloma

  This study tests whether inobrodib with pomalidomide and dexamethasone helps people with relapsed or refractory multiple myeloma more than the standard available therapy.

  Recruiting Phase 3 CellCentric Ltd. · Miami, Florida · NCT07772024

• Soursop tea in relapsed/refractory AML or multiple myeloma

  This pilot study tests whether drinking tea made from soursop leaves can help reduce cancer cells in people with relapsed or refractory AML or MM.

  Recruiting Early Phase 1 Cooper Norcross Health · Camden, New Jersey · NCT07771803

• CAR-T therapy for relapsed or refractory multiple myeloma

  This study tests a CAR-T therapy in people with multiple myeloma whose disease has come back or not responded to treatment.

  Recruiting at 2 sites Phase 2 National Institute of Blood and Marrow Transplant (NIBMT), Pakistan · Rawalpindi, Punjab Province and 1 other locations · NCT07689058

• Elranatamab given as outpatient in relapsed or refractory multiple myeloma

  This study tests a bispecific antibody called elranatamab, given in an outpatient setting to adults with relapsed or refractory multiple myeloma who have had prior therapies.

  Recruiting at 6 sites Phase 2 SCRI Development Innovations, LLC · Denver, Colorado and 5 other locations · NCT07637578

• Anti-BCMA CAR‑T therapy for adults with relapsed or refractory multiple myeloma

  This tests whether a patient's own engineered anti-BCMA CAR‑T cells can help adults whose multiple myeloma has come back or stopped responding to treatment and whether the approach is safe.

  Recruiting Phase 1/2 Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology · Minsk · NCT07477912

• Liposomal Curcumin in Multiple Myeloma: safety and dose finding

  This trial tests a novel liposomal curcumin infusion to see if it is safe and what highest tolerable dose is for adults whose multiple myeloma has returned or not responded to treatment.

  Recruiting Phase 1 University Health Network, Toronto · Toronto, Ontario · NCT07456605

• Off-the-shelf BCMA CAR‑T for relapsed or refractory multiple myeloma

  This trial will try a universal (allogeneic) BCMA-directed CAR‑T cell treatment for people with relapsed or refractory multiple myeloma to see if it is safe and can reduce disease.

  Recruiting Bioray Laboratories · Shanghai · NCT07248176

• HuL001 plus Lenalidomide/Dexamethasone for relapsed/refractory multiple myeloma

  Aimed at testing HuL001 together with Len/Dex to see if it helps people with relapsed or refractory multiple myeloma.

  Recruiting Phase 1/2 HuniLife Biotechnology, Inc. · Taipei · NCT07210047

• NT-I7 added to BCMA CAR-T therapy for relapsed or refractory multiple myeloma

  This trial tests whether giving NT-I7 after BCMA CAR-T therapy helps boost T-cell expansion and possibly improve responses in people with relapsed or refractory multiple myeloma.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT07200089

• Inobrodib with pomalidomide and dexamethasone for relapsed or refractory multiple myeloma

  This test tries to see if adding inobrodib to pomalidomide and dexamethasone helps people whose multiple myeloma has returned or stopped responding after standard treatments.

  Recruiting at 31 sites Phase 2 CellCentric Ltd. · Phoenix, Arizona and 30 other locations · NCT07096778

• Target IgG levels for people with multiple myeloma on BCMA-directed T-cell engager therapy

  This will test whether keeping IgG levels at 4–6 g/L works as well as 8–10 g/L to prevent severe infections in adults with relapsed or refractory multiple myeloma who are receiving BCMA-directed T-cell engager therapy.

  Recruiting at 2 sites Phase 4 CHU de Quebec-Universite Laval · Lévis, Quebec and 1 other locations · NCT07094048

• Sequential CAR-T therapy targeting BCMA and GPRC5D for relapsed or refractory multiple myeloma

  This will try sequential CAR-T cell therapy against BCMA and GPRC5D in people with relapsed or refractory multiple myeloma to see if it is safe and helps control the disease.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07032129

• Selinexor plus a commercial bispecific antibody for relapsed or refractory multiple myeloma

  This study will test whether adding selinexor to a commercial bispecific antibody helps adults with relapsed or refractory multiple myeloma reach deeper remissions and is safe.

  Recruiting Phase 2 Duke University · Durham, North Carolina · NCT06822972

• Early palliative care for patients with multiple myeloma and aggressive lymphoma

  This study is testing if early palliative care can improve the quality of life and comfort for people with multiple myeloma and aggressive lymphoma while they receive their usual cancer treatment.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT06485076

• Combination treatment for relapsed or refractory multiple myeloma

  This study is testing a new combination of lower-dose Selinexor, Ruxolitinib, and methylprednisolone to see if it can help people with relapsed or refractory multiple myeloma who have few treatment options left.

  Recruiting Phase 1 Oncotherapeutics · West Hollywood, California · NCT06225310

• Using All-trans Retinoic Acid with KPD for treating relapsed multiple myeloma

  This study is testing if a new combination of All-trans Retinoic Acid and a specific treatment can help people with relapsed multiple myeloma who haven't had success with other therapies.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06158412

• Combining venetoclax with isatuximab and dexamethasone for treating relapsed/refractory multiple myeloma

  This study is testing a new combination of medications to see if it can help people with relapsed or stubborn multiple myeloma who have a specific genetic marker feel better and respond to treatment.

  Recruiting at 2 sites Phase 2 Oncotherapeutics · West Hollywood, California and 1 other locations · NCT06115135

• Testing a new CAR T-cell therapy for patients with advanced B-cell cancers

  This study is testing a new CAR T-cell therapy to see if it can help adults with hard-to-treat B-cell cancers feel better and improve their health.

  Recruiting Phase 1 Technische Universität Dresden · Dresden · NCT05836896

• APRIL CAR-T cell therapy for relapsed multiple myeloma patients

  This study is testing a new CAR-T cell therapy for patients with relapsed multiple myeloma to see if it is safe and effective for those who haven't responded well to other treatments.

  Recruiting Early Phase 1 Zhejiang University · Hangzhou, Zhejiang · NCT04657861

• Combining Selinexor and Dexamethasone for Advanced Multiple Myeloma

  This study is testing if a new combination of selinexor and low-dose dexamethasone can help people with advanced multiple myeloma who haven't responded to other treatments.

  Recruiting at 6 sites Phase 2 Karyopharm Therapeutics Inc · Pátrai, Achaia and 15 other locations · NCT04414475

Related topics

Quick answers

How many Multiple Myeloma, Refractory clinical trials are recruiting right now?

21, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 10 countries. The most sites are in United States (9 trials), China (4 trials), Canada (3 trials), Pakistan (1 trial), Taiwan (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 7, Phase 1: 5, Phase 1/2: 3, Early Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →